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Abstract
Background: Trichosporon mycotoxinivorans is a recently described yeast-like fungal organism and its association as
a pathogen for patients with cystic fibrosis (CF) was reported previously. We show the clinical course of a CF
patient over 9 years as well as the applications of modern molecular and proteomic identification techniques of
this rare fungus.
Case presentation: We present the case of a 32-year-old male CF patient with sputum cultures continuously
positive with the anamorphic yeast T. mycotoxinivorans during 9 years. Furthermore, susceptibility testing of T.
mycotoxinivorans to different antifungals were performed. In addition, a rapid identification method of this novel
fungal pathogen with matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)
was applied using a simple extraction protocol.
Conclusions: Our case presentation confirms T. mycotoxinivorans as a potential emerging pathogen in patients with
CF. However, our CF patient showed mild symptoms over a very long time period of 9 years. A short MALDI-TOF MS
procedure allows reliable and rapid identification of T. mycotoxinivorans and therefore should facilitate further study on
the clinical relevance and epidemiology of this unusual fungal organism.
Keywords: Trichosporon mycotoxinivorans, Cystic fibrosis (CF), Internal transcribed spacer (ITS), Emerging pathogen,
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Background
The genus Trichosporon comprises 35 species of this
basidiomycetous yeast from which 6 are known to be
medically-relevant mainly in the immunocompromised
patient [1, 2]. They are ubiquitous yeasts, found in soil
and water and known as colonizers of skin and gastro-
intestinal tract of humans [1]. Trichosporon mycotoxini-
vorans was described for the first time in 2004, when it
was isolated from the hindgut of the lower termite
Mastotermes darwiniensis (Mastotermitidae) [2]. The
name of this species refers to the ability of T.
mycotoxinivorans to degrade certain mycotoxins, an
important characteristic which could be used for deacti-
vation of the respective mycotoxins in animal feeds [2].
Its association with cystic fibrosis (CF) patients was
reported for the first time in the USA in 2009 [3]. A
20-year-old male with CF died with histologically proven
T. mycotoxinivorans pneumonia. Another case of a fatal
disseminated coinfection with T. mycotoxinivorans,
Aspergillus fumigatus and Scedosporium apiospermum in
a CF patient, recipient of lung and liver transplant, was
published recently [4]. Kröner et al. demonstrated the
potential association of Trichosporon spp. with severe
exacerbations in CF patients [5]. On the other hand, the
results of the most recent study by Shah et al. showed
that the isolation of T. mycotoxinivorans from CF
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patients is not necessarily associated with significant
changes in clinical status [6]. Here we report on a CF
patient with repeated isolation of T. mycotoxinivorans in
respiratory specimens during the past 9 years.
Case presentation
A 32-year-old male was regularly followed in our clinic
because of CF. His lung function had been stable and is
slowly decreasing since the last 7 years with a moderate
irreversible airflow obstruction with an FEV1 of 60 %
(predicted). He was known to be suffering from a chronic
colonization with Staphylococcus aureus, Stenotrophomo-
nas maltophilia, and Pseudomonas aeruginosa for which
he has been treated repeatedly with oral antibiotics
(trimethoprim/sulfamethoxazole, doxycycline and amoxi-
cillin/clavulanic acid) as well as rarel intravenous
regimens with piperacillin/tazobactam and tobramycin.
He was put under permanent treatment with azithromy-
cin and intermittent adjunct of amikacin for inhalation.
Further he had a history of allergic bronchopulmonary
aspergillosis leading to a subacute clinical deterioration.
He was successfully treated with oral and inhaled steroids.
In 2007, a basidiomycetous yeast was isolated from
sputum of the patient. The colonies grew after 2 days of
incubation on Sabouraud agar (Becton Dickinson Diag-
nostic Systems, Allschwil, Switzerland), showing typical
“furry” appearance (Fig.1) and histopathology of the
bronchoalveolar lavage specimen showed not-specified
fungal structures (Fig. 2). The organism was identified as
Trichosporon species based on phenotypic features such
as the typical morphology of colonies with aerial whitish
mycelium (Fig. 1) and characteristic arthroconidia (Fig. 3)
as well as the use of the API® ID32C identification system
(bioMérieux, Geneva, Switzerland). Identification of the
Trichosporon isolate to the species level was performed in
2011, based on PCR amplification and sequencing of the
internal transcribed spacers (ITS), as well as the D1/D2
region of the 26S rRNA gene [7]. The investigated
sequence showed 100 % identity to reference
sequences of T. mycotoxinivorans. Our 1167-bp-long
sequence has been deposited in GenBank under
accession no. JQ266092. In 2012, matrix-assisted laser
desorption ionization-time of flight mass spectrometry
(MALDI-TOF MS) was performed for the first time
from colony material using the full ethanol-formic
acid extraction protocol as recommended by the
manufacturer. The analysis on the MALDI BioTyper
system with the BioTyper 3.0 SR software (Bruker
Daltonics GmbH, Bremen, Germany) resulted in highly
accurate species identification with scores higher than
2.200. The manufacturer recommends ≥2 log score for
species identification; 1.7 to 1.99 for genus identification;
and <1.7 as unreliable [8]. Subsequent isolates were tested
with a simple “short extraction” protocol, consisting of
addition of 1 μl of 70 % formic acid to the smears on the
Fig. 1 Colonies of T. mycotoxinivorans on sheep blood agar,
40-fold magnification
Fig. 2 Fluorescence microscopy of bronchoalveolar lavage sample;
Fungiqual A, 400-fold magnification
Fig. 3 Microscopy of T. mycotoxinivorans showing arthroconidia,
400-fold magnification
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plate before application of the matrix solution [9]. The
“short extraction” yielded scores ranging from 1.866 to
2.136 (average 1.989, median 1.984). The organism was
isolated repeatedly from respiratory specimens during the
period from 2007 to 2016. An overview of the microbio-
logical results is shown in Table 1. The susceptibility test-
ing of the strain was performed in 2012 and 2013 using a
commercial microtitre system (YeastOne, Trek Diagnostic
Systems, Thermo Fisher Scientific Schweiz AG, Reinach,
Switzerland). The results of the susceptibility testing are
shown in Table 2. The strain exhibited high level resist-
ance to the echinocandins (anidulafungin, micafungin,
caspofungin) and variable susceptibility to amphotericin B
and the triazoles (fluconazole, itraconazole, voriconazole
and posaconazole). Due to further clinical deterioration,
an antifungal therapy with voriconazole was initiated
(200 mg twice a day). Clinical amelioration was observed
within 6 weeks. However, a clinical relapse occurred after
9 months later and T. mycotoxinivorans was again identi-
fied. After detection of a large quantity of two morpho-
types of Trichosporon mycotoxinivorans the therapy was
changed to itraconazole with a very good clinical response
and lung functional response. Over the years the clinical
course was characterized by recurrent worsening of the
respiratory situation expressed by a mostly mild symptom-
atology with a marked reduction of the detectable T.
mycotoxinivorans quantity and satisfying stable clinical re-
sults after the treatment with triazoles. It is possible that
by using voriconazole, A. fumigatus has been suppressed
together with T. mycotoxinivorans. There might have been
also a reduction of the antigenic stimulus for bronchial in-
flammation as it has been seen in therapies with itracona-
zole. Because of the stability of the clinical course after the
treatment with voriconazole, a long term suppressive ther-
apy with antifungal agents was not applied.
The systematic search for Trichosporon colonization in
our microbiological data sheets of 64 CF patients, 10
patients after lung transplantation, and 32 patients with
bronchiectasis did not reveal any other patients with
Trichosporon spp.
In addition to arthroconidia, T. mycotoxinivorans may
sometimes microscopically display large fusiform cells
with granular contents called fusiform giant cells [10].
This feature, however, should not be used for species
identification, since fusiform giant cells may also appear
in other Trichosporon spp. like T. loubieri and T.
vanderwaltii [10, 11]. Furthermore, in some T. mycotoxi-
nivorans isolates like the one described in this case
report or communicated by Hickey et al. [3], the
fusiform giant cells may not be present. This feature is
probably culture medium or culture age dependent. To
date, the only reliable identification of this yeast to spe-
cies level could be achieved by sequencing, available only
in specialized clinical laboratories. The MALDI-TOF MS
Table 1 Chronology of microbiological findings in the sputum
samples of the patient
Year Organisms isolated, amountsa

























2013 Staphylococcus aureus, +++
Stenotrophomonas maltophilia, +
Mould, not identified, +
Oral flora, +
Trichosporon mycotoxinivorans, +




2015 Staphylococcus aureus, ++
Oral flora, ++
Trichosporon mycotoxinivorans, ++
2016 Staphylococcus aureus, ++
Oral flora, ++
Trichosporon mycotoxinivorans, ++
aAmounts: +, few; ++, moderate; +++, numerous
Goldenberger et al. BMC Infectious Diseases  (2016) 16:601 Page 3 of 5
identification is becoming the standard for isolate identi-
fication in many laboratories. In contrast to Hirschi et
al. [4], we were able to reliably identify the Trichosporon
yeast to the species level using the MALDI-TOF MS
identification. Our findings are in congruence with suc-
cessful identification of this pathogen by Hickey and col-
leagues [3]. However, in our study, we describe for the
first time the identification of this yeast by using the
“short extraction” on-plate protocol for the routine diag-
nostics. As the scores obtained were somewhat lower
than those with the full extraction protocol, we propose
using lower species cutoff values for identification of T.
mycotoxinivorans. Our proposal is consistent with studies
of Vlek and Van Herendael [9, 12], which consider a spe-
cies cutoff value of as low as 1.7 as appropriate for routine
yeast identification in clinical laboratories. MALDI-TOF
MS, as a rapid and reliable identification tool may facili-
tate further study on the reservoir and the epidemiologic
link of T. mycotoxinivorans to CF patients. Concerning its
antifungal susceptibility, the genus Trichosporon presents
increased in vitro resistance to common antifungal agents
such as amphotericin B and echinocandins [1, 2], but also
strains resistant to multiple triazoles have been identified
[3]. Due to variable susceptibility patterns to triazoles,
which are considered as therapy of choice [3], every strain
isolated should be tested for antifungal susceptibility. At-
tempts to treat our patient with triazoles did not lead to
an eradication of T. mycotoxinivorans, but to an improve-
ment of the clinical symptoms.
Conclusions
In summary, our report on a CF patient colonized with
T. mycotoxinivorans for a long period of 9 years suggests
that this yeastlike organism may be associated with clin-
ical deterioration, and the patient’s condition improved
under therapy with voriconazole and itraconazole. T.
mycotoxinivorans could be successfully identified with a
simple on-plate MALDI-TOF MS short extraction
protocol that may facilitate further study on the reser-
voir and the epidemiologic link of T. mycotoxinivorans
to CF patients and immunocompromised persons.
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